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Abstract
NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-
electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic
activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be
resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated
in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and
chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and
IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the
log-rank test. Cox models were used to assess the impact of covariates on outcomes. Among 152
patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The
presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the
heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a
multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age <60 (HR=0.67, p=0.04), PS 1
(HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100
mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an
independent predictor of poor overall survival in individuals with resected stages II and IIIa
NSCLC. Although the basis for the NQO1 association with decreased survival requires additional
evaluation, NQO1 may represent a biomarker for guiding individualized therapy.
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Introduction
Lung cancer is the leading cause of cancer death in the United States, with 219440 new
diagnoses and 159390 deaths estimated for 2009 (1). Lung cancer is the most common cause
of cancer death among both men and woman in industrialized nations (2). Both
chemotherapy and radiotherapy are utilized to treat locally advanced or metastatic tumors.
Moderate survival improvements are reported for patients with inoperable disease who
received chemotherapy as well as for patients who have received platinum based
chemotherapy following surgery (3-6). Despite treatment, overall survival remains poor, not
all patients respond to therapy, and patients receiving chemotherapy experience significant
toxicity (4). Genetic markers are a potential method to identify patients most likely to
benefit from chemotherapy or radiotherapy.
NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the
two-electron reduction of quinones into hydroquinones. NQO1 contains one characteristic
polymorphism (NQO1*2), a C→T transition at bp 609 that results in a proline to serine
substitution at codon 187 (7,8). Individuals homozygous for NQO1*2 have essentially no
active enzyme (9), while those who are heterozygotes have intermediate activity when
compared to NQO1*1 homozygotes (10). The decreased activity associated with this
polymorphism is mediated by two mechanisms: i) the polymorphism is in the active site of
NQO1, and ii) the NQO1*2 protein is degraded rapidly via the ubiquitin-dependent pathway
(half-life of wild-type NQO1 >18 h and the half-life of variant NQO1*2 is 1.2 h) (10).
A lack of NQO1 may increase the generation of semiquinones rather than hydroquinones,
from the quinines found in cigarette smoke. Polymorphisms in NQO1 have therefore been
evaluated as modifiers of lung cancer risk and have been the subject of two meta-analysis.
Chao and colleagues (11) reported that in Caucasian populations, there was an increased
prevelance of the variant allele among ever smokers with lung cancer (OR, 1.08; 95% CI,
0.96-1.22), but not among never smokers (OR, 0.97; 95% CI, 0.62-1.54). However,
Kiyohara et al (12) showed the opposite effect in a Japanese cohort where the allele was
significantly associated with decreased risk of lung cancer [random effects odds ratio (OR) =
0.70]. The role of NQO1 in lung cancer pathogenesis appears small.
NQO1 has also been studied as a predictor of chemosensitivity and radiosensitivity and
overexpression has typically been associated with increased chemosensitivity and
radiosensitivity (13). NQO1 gene expression is induced in response to xenobiotics,
antioxidants, UV light, ionizing radiation and cisplatin. Additionally, wild-type NQO1 binds
to and stabilizes both mutant and wild-type p53 under conditions of oxidative stress or after
exposure to γ-irradiation. Degradation of p53 is mediated by two alternative pathways,
ubiquitin-independent or ubiquitin-dependent. The ubiquitin-independent pathway is
regulated by NQO1 and is mediated via the 20S proteasome (13).
Song et al (14) demonstrated that NQO1 genotype significantly influenced loco-regional
recurrence in Korean patients with completely resected stage II or IIIa NSCLC who were
treated with adjuvant radiation and sometimes adjuvant chemotherapy [wild-type (NQO1*1/
*1) 6.3% (2/32), heterozygous patients 8.1% (5/62), NQO1*2/*2 27.3% (6/22)].
Multivariate analysis revealed that NQO1 genotype and pathologic nodal stage were
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statistically significant predictive factors for loco-regional recurrence-free survival, but not
overall survival.
Individuals with NQO1*2 polymorphisms may be both chemoresistant and radiation
resistant. The current study was performed to determine the effect of the NQO1 genetic




ECOG 3590 was a randomized, prospective trial of adjuvant therapy in patients with
resected stages II or IIIa NSCLC (15). All patients had complete resection of their tumor and
mediastinal lymph node sampling or dissection. Eighty-five percent were Caucasian.
Following stratification by weight loss, histology, nodal biopsy technique and lymph node
status, patients were randomized to receive chemotherapy (cisplatin 60 mg/m2 IV on day 1
and etoposide 120 mg/m2 days 1-3) with concurrent RT (50.4 Gy in 28 daily fractions) or
RT alone.
Patients enrolled in ECOG 3590 were also eligible for enrollment in ECOG 4592 (16), a
study designed to evaluate the prognostic value of p53 mutations in exons 5-8 which were
determined by single-strand confirmation polymorphism (SSCP) analysis. Genomic DNA
extracted from submitted paraffin blocks were utilized. Patients enrolled in ECOG 3590
gave permission to use samples for future studies. The current study design was reviewed
and approved by the University of Wisconsin Institutional Review Board.
Genotyping
Genomic DNA extracted from the ECOG 4592 samples was stored at -80°C and variations
in the NQO1 gene were analyzed by pyrosequencing. Initial polymerase chain reaction
(PCR) primers were designed using Primer Express version 1.5 (ABI, Foster City, CA) and
consisted of forward primer (5′-CTGATGGAATTGGTTGACTTA-3′), and reverse primer
[5′(Biotin)-TCTGGTGATCACCCAAGGCT-3′] to amplify a portion of the NQO1 gene.
The forward pyrosequencing primer (5′-GTGGCTTCCAAGTCTTA-3′) was designed using
Pyrosequencing SNP Primer Design Version 1.01 software
(http://www.pyrosequencing.com). Primers were obtained from Integrated DNA
Technologies (Coralville, IA). PCR was carried out using Amplitaq Gold PCR master mix
(ABI), 5 pmole of each primer, and 10 ng DNA, on an MJ Research PTC-100 thermal cycler
(Waltham, MA). Reactions were denatured initially at 93°C for 20 min, then cycled at 95°C
for 30 sec, 55°C for 30 sec and 72°C for 30 sec for 55 cycles, followed by a final elongation
step at 72°C for 5 min. Pyrosequencing was carried out as previously described using a
PSQ96 instrument and software (Biotage AB, Uppsala, Sweden) (32). Genotype was called
variant if it differed from the Refseq consensus sequence for the SNP position. To ensure
proper amplification and the absence of contamination, each PCR and pyrosequencing run
contained no template controls or cancer cell line positive controls.
Statistical analysis
Polymorphisms were classified into two groups, heterozygous/wild-type and variant. Wild-
types and heterozygotes were combined as NQO1 activity is similar. OS, defined as the time
from randomization to death from any cause, was estimated using the Kaplan-Meier method.
Differences between the polymorphism status groups were analyzed using the log-rank test.
Fisher's exact test and the Kruskal-Wallis rank sum test were used to compare baseline
variables between the two polymorphism groups. Cox models were used to assess the
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univariate association between baseline variables and overall survival. Variables significant
at the 0.10 level were fitted to a multivariable Cox proportional hazards model and
backwards selection was used to select the final model.
Results
Four hundred and eighty-eight patients were enrolled in ECOG 3590, of whom 217 entered
ECOG 4592. Among 152 patients with assessable samples, 24 (16%) had variant NQO1.
Most demographic variables were balanced between the two NQO1 groups (Table I).
However, a greater proportion of patients with mutated p53 was present in the heterozygous/
wild-type NQO1 group, (p=0.04).
Median follow-up was 139 months. One hundred and twenty-three (81%) patients had died.
Median OS in the heterozygous/wild-type group was 42.3 months (95% CI 35.9-66.3 mos)
vs. 33.5 months (95% CI 16.2-80.9 mos) in the variant group (p=0.04, Fig. 1). Among
patients receiving RT only, no difference in OS was observed (45.2 mos (95% CI 35.9-91.8
mos) vs. 53.4 mos (95% CI 29.2-Inf); p=0.49, Fig. 2). However, among those patients who
received chemoradiotherapy a significant difference in median OS in favor of the
heterozygous/wild-type group was observed (40.0 months (95% CI 30.8-80.6 mos) vs. 16.2
months (13.6-Inf mos), p=0.007, Fig. 3).
Univariate Cox proportional hazards models (Table II) revealed that overall survival was
associated with: NQO1 status, age, race, performance status, cardiovascular disease, alkaline
phosphatase (mg/ml) and TNM stage. Treatment and NQO1 status were not statistically
significant when adjusted for these two factors alone (p=0.16). A multivariable Cox model
revealed variant NQO1 (HR=1.58, p=0.05), age <60 (HR 0.67, p=0.04), PS 1 (HR=1.47,
p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100 mg/ml
(HR= 0.59, p=0.005) were all significant predictors of OS. A treatment by NQ01 status
interaction test was not statistically significant (p=0.16).
Discussion
Our study is the first to report that NQO1*2/*2 may be an independent predictor of poor
overall survival in individuals with resected stages II and IIIa NSCLC. These results are in
contrast with Song and colleagues who identified a decrease in locoregional recurrence-free
survival in NQO1*2/*2 patients, but not in overall survival. This may be related to the
different length of median follow-up (49.2 months compared to 139 months), and
chemotherapy differences (cisplatin/vinorelbine allowed vs. patients randomized to
cisplatin/etoposide or no chemotherapy). Locoregional recurrence-free survival was not
evaluated as part of E3590. These results suggest that NQO1*2/*2 may be considered an
independent predictor of poor survival for patients with NSCLC. Individuals with NQO1*2/
*2 have no NQO1 activity, and subsequently lose NQO1 stabilization of three tumor
suppressors p53 (17-19), p73a (20) and p33 (21), by inhibiting their breakdown via the 20S
proteosome. Lack of stabilization may lead to a more aggressive tumor biology and lack of
responsiveness to chemotherapy and radiation therapy (22-25).
These data suggest that RT is the optimal therapy for individuals with NQO1*2/*2. The lack
of a difference in OS when analyzed by treatment and NQO1 status (p=0.016) may be
related to inadequate power.
In this study, patients who were NQO1*2/*2 were more likely to be p53 wild-type. Since
NQO1*1 is known to bind to and stabilize both mutant and wild-type p53 (and these
genotypes should have opposite prognostic effects), we hypothesize that that p53 status
becomes important only in the absence of NQO1 activity. That the role of p53 in lung cancer
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prognosis has been the subject of dozens of paper and two meta-analyses (25,26) without
resolution of the question, lends support to this hypothesis. The association between
NQO1*2/*2 and p53 wild-type suggests that these genes may be important in lung cancer
pathogenesis.
Our study has several limitations, including that is was as unplanned retrospective analysis,
had limited in power to detect treatment effects and used of SSCP for identifying p53
mutations. While p53 mutations were evaluated in exons 5-8, the specific mutation is not
identifiable by SSCP. Therefore, the effect of the mutation on p53 protein expression and
the interaction between NQO1 and the mutant p53 is unknown. However, this study does
have the advantage of utilizing data from a large, randomized multi-institutional trial with
mature survival data.
In summary, NQO1*2/*2 independently predicts poor survival in completely resected
NSCLC stages II and III patients. In addition, NQO1*2 is associated with p53 wild-type.
Prospective trials and determination of specific p53 mutations are needed to confirm and
define the relationship of NQO1, p53 and NSCLC. The results of the current study
demonstrate that evaluation of NQO1 polymorphisms may be an important consideration in
individualizing the treatment of lung cancer.
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Kaplan-Meier curve comparing NQO1*1/*1 and NQO1*1/*2 to NQO1*2/*2 in all patients
median OS in the heterozygous/wild-type group was 42.3 vs. 33.5 months in the variant
group (p=0.04).
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Kaplan-Meier curve comparing NQO1*1/*1 and NQO1*1/*2 to NQO1*2/*2 in patients
receiving RT only, no difference in OS was observed (p=0.49).
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Kaplan-Meier curve comparing NQO1*1/*1 and NQO1*1/*2 to NQO1*2/*2 in patients
receiving CRT, demonstrating a significant difference in median OS in favor of the
heterozygous/wild-type group was observed (40.0 vs. 16.2 months, p=0.007).
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